Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-proven DLBCL which meet the criteria of any of the 4 subgroups~* Transformed DLBCL from a previous indolent NHL which meet the criteria of any of the 4 subgroups and have received at least one standard chemotherapy regimen for aggressive NHL or a biopsy upon progression of disease has been obtained to confirm the presence of DLBCL. The concomitant presence of a component of low grade lymphoma will NOT exclude participation~* Measurable disease per Standardized Response Criteria for Non-Hodgkin's Lymphoma~* Prior gemcitabine therapy is allowed.~* Negative pregnancy test~Exclusion Criteria:~* No history of life-threatening reactions to rituximab.~* No history of gemcitabine intolerance; prior gemcitabine therapy is allowed.~* No history of malignancy in the last 5 years (basal cell carcinoma of the skin excluded).~* No central nervous system or cerebrospinal fluid involvement~* No other investigational drugs received within 30 days prior to being registered for protocol therapy.~* No active infections.~* No current breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Rituximab + Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Based on this trial design, predict the completion outcome and termination type (if applicable).